Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286468 · ClinicalTrials.gov registry record · Phase 3
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00286468 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 500 participants.
The verdict
NCT00286468, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.
Interventions
- DRUG Glyburide
- DRUG Alogliptin and glyburide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00286468
The ClinicalTrials.gov registry entry for NCT00286468 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glyburide is the first listed.
NCT00286468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00286468 about?
NCT00286468 is a clinical study titled "Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.
What is the current status of trial NCT00286468?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2006-04. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00286468?
The interventions under investigation include: Glyburide (DRUG), Alogliptin and glyburide (DRUG).
Who is sponsoring clinical trial NCT00286468?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.